AI assistant
Wave Life Sciences Ltd. — Director's Dealing 2018
Feb 22, 2018
31900_dirs_2018-02-21_19c779a4-4351-41f2-a72f-657a6392442d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Wave Life Sciences Ltd. (WVE)
CIK: 0001631574
Period of Report: 2018-02-16
Reporting Person: Francis Chris (See Remarks)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-02-16 | Ordinary Shares | S | 723 | $51.80 | Disposed | 22077 | Direct |
| 2018-02-16 | Ordinary Shares | M | 9412 | $2.48 | Acquired | 31489 | Direct |
| 2018-02-16 | Ordinary Shares | S | 9412 | $55.00 | Disposed | 22077 | Direct |
| 2018-02-20 | Ordinary Shares | M | 11504 | $2.48 | Acquired | 33581 | Direct |
| 2018-02-20 | Ordinary Shares | S | 11504 | $55.95 | Disposed | 22077 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-02-16 | Share Option (right to buy) | $2.48 | M | 9412 | Disposed | 2025-03-10 | Ordinary Shares (9412) | Direct |
| 2018-02-20 | Share Option (right to buy) | $2.48 | M | 11390 | Disposed | 2025-03-10 | Ordinary Shares (11390) | Direct |
| 2018-02-20 | Share Option (right to buy) | $2.48 | M | 114 | Disposed | 2025-03-10 | Ordinary Shares (114) | Direct |
Footnotes
F1: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017.
F2: On February 16, 2018, the reporting person sold 723 ordinary shares solely to cover taxes associated with the vesting of restricted share units on February 15, 2018. These sales were made pursuant to a 10b5-1 Trading Plan.
F3: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $51.55 to $51.95 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F4: The share option represented a right to purchase a total of 20,802 ordinary shares, 25% of which became exercisable on April 15, 2015, and the remaining shares vest in 36 equal monthly installments thereafter.
F5: The share option represented a right to purchase a total of 126,174 ordinary shares, 25% of which became exercisable on April 15, 2015, and the remaining shares vest in 36 equal monthly installments thereafter.